Lipid Lowering Therapy, an essential aspect of cardiovascular care, is designed to address and control elevated cholesterol and triglyceride levels within the bloodstream. By employing various medications like statins, fibrates, or cholesterol absorption inhibitors, this therapeutic approach aims to bring about a significant reduction in lipid levels, thereby reducing the risk of cardiovascular diseases, including heart attacks and strokes. The significance of Lipid Lowering Therapy lies in its ability to curtail one of the primary risk factors associated with cardiovascular complications. Regular monitoring of lipid levels and the implementation of personalized treatment plans are key elements in ensuring the effectiveness of Lipid Lowering Therapy. Healthcare professionals tailor interventions based on individual patient profiles, considering factors such as age, medical history, and existing conditions. This personalized approach enhances the precision and success of the therapy, emphasizing its role in holistic cardiovascular management.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States